» Articles » PMID: 33276741

Idiopathic Multicentric Castleman Disease with Sjögren's Syndrome and Secondary Membranous Nephropathy: a Case Report and Review of the Literature

Overview
Journal BMC Nephrol
Publisher Biomed Central
Specialty Nephrology
Date 2020 Dec 5
PMID 33276741
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Idiopathic multicentric Castleman disease (iMCD) is an uncommon lymphoproliferative disorder and lacks treatment consensus. Herein, we report a case of iMCD complicated with Sjögren's syndrome (SS) and secondary membranous nephropathy (SMN).

Case Presentation: A 45-year-old female with dry mouth for 3 months and anasarca and proteinuria for 2 months was admitted. She also experienced chest tightness, wheezing, fever, weight loss, moderate proteinuria and hypoalbuminemia. A computed tomography (CT) scan revealed a tissue mass in the thymus area and enlarged multiple lymph nodes. Her symptoms did not improve after resection of the thymus mass. The pathological findings were "reactive hyperplasia of the mediastinal lymph nodes and thymic hyperplasia". Lymph node biopsy findings confirmed iMCD with human herpes virus-8 (HHV-8) negativity. Based on anti-nuclear antibody (ANA) 1:320, anti-SSA and anti-SSB antibody positivity, salivary flow less than 0.1 ml/min and lip biopsy with focal lymphocytic sialadenitis, SS was diagnosed. Kidney biopsy showed secondary membranous nephropathy with endocapillary cell proliferation and infiltration of plasma cells and lymphocytes in the tubulointerstitium. Serum interleukin-6 (IL-6) levels were significantly increased, and therapy with tocilizumab (anti-IL-6 receptor antibody) worked well. The combination of cyclophosphamide (CyS) with methylprednisolone (MP) maintained satisfactory remission.

Conclusions: Our case of iMCD with SS and SMN is rare. There is a need for increased awareness of the disease to avoid unnecessary procedures and misdiagnoses. IL-6 was extremely high, and there was a rapid response to anti-IL-6 receptor agents. The combination of CyS with MP maintained complete remission.

Citing Articles

Multicentric Castleman Disease: A Case Report of an Arab Female.

Mansour M, Zayat A Cureus. 2024; 16(10):e71112.

PMID: 39525135 PMC: 11543861. DOI: 10.7759/cureus.71112.


Castleman's disease in the rheumatological practice.

Schmalzing M, Sander O, Seidl M, Marks R, Blank N, Kotter I Z Rheumatol. 2024; 83(Suppl 3):289-298.

PMID: 39174716 PMC: 11655606. DOI: 10.1007/s00393-024-01560-5.


Development of a nomogram for membranous nephropathy prediction in patients with primary Sjögren's syndrome: a 6-year retrospective study.

Guo L, Zhao S, Liu X Front Immunol. 2024; 15:1320880.

PMID: 38633257 PMC: 11021693. DOI: 10.3389/fimmu.2024.1320880.


TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.

Shirakashi M, Nishida Y, Nakashima R, Fujimoto M, Hiwa R, Tsuji H Sci Rep. 2024; 14(1):2889.

PMID: 38311632 PMC: 10838910. DOI: 10.1038/s41598-024-53413-5.


How to Choose the Right Treatment for Membranous Nephropathy.

Peritore L, Labbozzetta V, Maressa V, Casuscelli C, Conti G, Gembillo G Medicina (Kaunas). 2023; 59(11).

PMID: 38004046 PMC: 10673286. DOI: 10.3390/medicina59111997.


References
1.
van Rhee F, Greenway A, Stone K . Treatment of Idiopathic Castleman Disease. Hematol Oncol Clin North Am. 2017; 32(1):89-106. DOI: 10.1016/j.hoc.2017.09.008. View

2.
Furutera N, Fukunaga N, Okita J, Suzuki T, Suenaga Y, Oyama Y . Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. CEN Case Rep. 2020; 10(1):35-41. PMC: 7829305. DOI: 10.1007/s13730-020-00511-8. View

3.
Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J . Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2014; 56(5):1252-60. DOI: 10.3109/10428194.2014.953145. View

4.
Sitenga J, Aird G, Ahmed A, Silberstein P . Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease. Patient Relat Outcome Meas. 2018; 9:35-41. PMC: 5769562. DOI: 10.2147/PROM.S140011. View

5.
Dispenzieri A, Armitage J, Loe M, Geyer S, Allred J, Camoriano J . The clinical spectrum of Castleman's disease. Am J Hematol. 2012; 87(11):997-1002. PMC: 3900496. DOI: 10.1002/ajh.23291. View